Wednesday, April 22, 2020, from 11:15 am–11:45 am ET.
Stephanie Pasas-Farmer, Ph.D., President and Founder, Ariadne
COVID-19 pandemic has not only disrupted our lives on all fronts, it has also exposed our need to focus on the highest quality and safety in testing. With insufficient testing and false-negative results, COVID-19 testing has shown how devastating insufficient testing can be for our community on a global scale. However, experiencing oversight of the importance of safety testing is not a new occurrence. Bioanalysis, due to its critical nature in drug development has seen its fair share of devastating testing failures. Taking the lessons learned from this current health crisis, let’s come together to understand the following: why this happened; areas of risk in our own industry; and how we can apply these lessons to our own systems and processes to avoid similar failures.